Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Core Insights - Allarity Therapeutics has made significant progress in the clinical development of stenoparib, a dual PARP and WNT pathway inhibitor, particularly in the treatment of advanced ovarian cancer, with FDA Fast Track designation received for accelerated development [2][5][6]. Clinical and Drug Development Progress - In 2025, Allarity advanced stenoparib towards pivotal trials and FDA approval, initiating a new Phase 2 clinical trial protocol aimed at optimizing dosing and refining patient selection for platinum-resistant ovarian cancer [2][6]. - The company launched its first combination study of stenoparib with temozolomide for recurrent small cell lung cancer, funded by the U.S. Veterans Administration, expanding the drug's potential applications [3][10]. - Durable clinical benefits were observed in patients treated with stenoparib for nearly 30 months, indicating its long-term therapeutic potential [6]. Financial Performance - As of December 31, 2025, Allarity reported a cash position of $14.7 million, down from $19.5 million in 2024, but with a runway extending into mid-2028 [5][9]. - The company generated $320 thousand in revenue for the year ended December 31, 2025, compared to no revenue in 2024 [11]. - Research and Development (R&D) expenses increased to $6.6 million in 2025 from $6.1 million in 2024, while General and Administrative (G&A) expenses decreased significantly to $6.3 million from $11.4 million [11]. Leadership and Corporate Development - Allarity strengthened its leadership team in 2025, appointing Jeff Ervin as Chief Financial Officer and Jesper Høiland to the Board of Directors, enhancing governance and strategic direction [7][10]. - The company expanded its DRP® companion diagnostic platform through licensing agreements, aiming for broader utilization of its patient-selection technology [10][12]. Recent Financing - In March 2026, Allarity closed a $20 million non-convertible debt financing with Streeterville Capital to support the advancement of stenoparib and extend its cash runway [10].